A Phase 3 trial of Fianlimab (REGN3767, ANTI-LAG-3) + Cemiplimab versus Pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
For more information please visit: https://clinicaltrials.gov/ct2/show/NCT05352672?term=R3767-ONC-2011&draw=2&rank=1
Comments